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ARTICLE
Multiplex secretome engineering enhances
recombinant protein production and purity
Stefan Kol 1✉, Daniel Ley1, Tune Wulff1, Marianne Decker1, Johnny Arnsdorf1, Sanne Schoffelen 1,
Anders Holmgaard Hansen 1, Tanja Lyholm Jensen1, Jahir M. Gutierrez2,3, Austin W. T. Chiang2,4,
Helen O. Masson2,3, Bernhard O. Palsson1,2,3,4, Bjørn G. Voldborg1, Lasse Ebdrup Pedersen1,
Helene Faustrup Kildegaard1, Gyun Min Lee1,5 & Nathan E. Lewis2,3,4✉
Host cell proteins (HCPs) are process-related impurities generated during biotherapeutic
protein production. HCPs can be problematic if they pose a significant metabolic demand,
degrade product quality, or contaminate the final product. Here, we present an effort to
create a “clean” Chinese hamster ovary (CHO) cell by disrupting multiple genes to eliminate
HCPs. Using a model of CHO cell protein secretion, we predict that the elimination of
unnecessary HCPs could have a non-negligible impact on protein production. We analyze the
HCP content of 6-protein, 11-protein, and 14-protein knockout clones. These cell lines exhibit
a substantial reduction in total HCP content (40%-70%). We also observe higher pro-
ductivity and improved growth characteristics in specific clones. The reduced HCP content
facilitates purification of a monoclonal antibody. Thus, substantial improvements can be
made in protein titer and purity through large-scale HCP deletion, providing an avenue to
increased quality and affordability of high-value biopharmaceuticals.
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Host cell proteins (HCPs) that are released from dead cellsand secreted from viable cells accumulate extracellularlyduring mammalian cell culture, potentially impairing
product quality1,2 and posing an immunogenic risk factor3. HCPs
must be reduced to low levels (<1–100 ppm) in all cell-derived
protein biotherapeutics before final product formulation, putting
a great demand on downstream purification. Depending on titer,
downstream processing comprises up to 80% of the entire pro-
duction costs of a monoclonal antibody (mAb)4. In the produc-
tion of a mAb, protein A affinity capture is often employed as a
generic first step, followed by two or three orthogonal polishing
steps5. Although the concentrations of HCPs in cell culture
harvests are reduced to acceptable levels after these purification
steps, certain HCPs can escape an entire purification process and
remain in the final product at levels that may affect product
quality and stability, cause an immunogenic reaction, or display
residual activity6,7. It is therefore of utmost importance to closely
monitor and identify HCPs to ensure their removal from bio-
therapeutic products. Enzyme-linked immunosorbent assay
(ELISA) is typically used in industrial processes to monitor
the total HCP content, but gives no information on specific
HCP components8. Proteomic analysis, such as two-dimensional
gel electrophoresis and/or mass spectrometry (MS), can therefore
be employed to identify specific HCPs6,9,10. Although many
studies have focused on identification, only a few efforts have
been made to remove troublesome HCP moieties by host cell line
engineering1,2,11,12.
Concerning CHO HCPs that affect product quality, a
matripase-1 knockout cell line was recently created that prevents
degradation of recombinant proteins2. A knockout cell line has
also been created devoid of lipoprotein lipase (Lpl) activity1. Lpl is
a difficult-to-remove HCP that degrades polysorbate in mAb
formulations, and targeted mutation resulted in abolishment of
Lpl expression and reduced polysorbate degradation without
substantial impact on cell viability. In a recent study, the HCPs
Annexin A2 and cathepsin D were removed12. Although the
authors do not confirm loss of activity, the knockouts do not
adversely affect cell growth. In addition, knockout of a serine
protease was shown to eliminate proteolytic activity against a
recombinantly expressed viral protein11. These previous efforts
targeted single genes, but mammalian cells can secrete a few
thousand HCPs9, so CRISPR technology could be used to target
multiple genes simultaneously by simply expressing multiple
sgRNAs together with a single Cas9 nuclease13,14.
Here, we demonstrate substantial reductions in HCP content
can be obtained through targeted genome editing, guided by
omics analyses. Specifically, we used a systems biology compu-
tational model to show that the removal of multiple HCPs could
free up a non-negligible amount of energy. We then used pro-
teomics to help identify target HCPs and subsequently applied
multiplex CRISPR-Cas9 to disrupt up to 14 genes coding for
proteins that are abundant in harvested cell culture fluid (HCCF),
difficult-to-remove during downstream processing, or have a
potentially negative impact on product quality. We analyzed HCP
content of a 6-protein, 11-protein, and 14-protein knockout and
characterized their growth in shake flasks, Ambr bioreactors, and
DASGIP bioreactors. We observed a substantial reduction of total
HCP content in the 6xKO (~40%), 11xKO, and 14xKO (60–70%)
cell lines. Depending on the cell line and growth conditions, we
also observed increased mAb productivity and improved growth
characteristics. When measuring HCP content and mAb titer at
the different stages of a three-step purification process (using
protein A and two ion exchange chromatography steps), we
observed a strong reduction in HCP content, increased HCP log
reduction values (LRV) of protein A affinity chromatography,
and decreased HCP ppm values. Thus, we demonstrate that
superior CHO production host cell lines can be produced by
eliminating specific HCPs. The dramatically lowered HCP ppm
values during purification of a mAb will facilitate downstream
processes. These HCP-reduced knockouts can be combined with
additional advantageous genetic modifications, such as the pro-
duction of glycoengineered proteins15–18, higher viability during
long culture times19, viral resistance or elimination20–22, and/or
clones with higher protein production stability of mAbs23, to
create predictable upstream and downstream processes with full
control over critical process parameters.
Results
CHO cells spend substantial resources on the secretome. There
are several potential advantages to the removal of HCPs,
including the elimination of immunogenic proteins or proteins
that degrade product quality. However, the question remains
regarding the bioenergetic investment made by the host cells on
the secreted fraction of their proteome. To evaluate the resource
and bioenergetic investment of CHO cells into their secretome,
we calculated the cost of each protein using a model of CHO cell
protein secretion24, scaled by its expression in RNA-Seq data25.
In CHO-S cells, we found that 39.2% of the resources are dedi-
cated to producing membrane and secreted proteins, most of
which are processed through the secretory pathway (Fig. 1a). In
all, 10.2% of cell resources were explicitly dedicated to secreted
proteins with signal peptides, and a relatively small number of
secreted proteins account for the majority of the bioenergetic cost
and use of the secretory pathway. Furthermore, we anticipate that
the cost for secreted proteins is likely higher since these proteins
are not turned over and recycled like intracellular and membrane
proteins. Thus, there is great potential to free up cellular resources
and secretory capacity, in addition to improving product quality
by eliminating unnecessary HCPs.
Target selection and verification. To decrease contaminating
HCP secretion and free up resources for CHO cell growth and
protein production, we identified targets based on three criteria:
(i) being abundant in CHO supernatants as analyzed by mass
spectrometry (Supplementary Data 1), (ii) being a difficult-to-
remove impurity in downstream processing26–29, and (iii) having
a negative impact on product quality1,30,31. To remove the genes,
we subjected the cell lines in this study to 4 cycles of CRISPR-
Cas9-mediated multiplex gene disruption. In the first round, the
gene encoding Metalloproteinase inhibitor 1 (Timp1) was dis-
rupted. In the second round, the genes encoding Biglycan (BGN),
Galectin-3-binding protein (LGALS3BP), Nidogen-1 (NID1.1
and NID1.2), and Cathepsin D (CTSD) were disrupted, resulting
in the 6xKO cell line. In the third round, the genes encoding N
(4)-(Beta-N-acetylglucosaminyl)-L-asparaginase (Aga), Endo-
plasmic reticulum resident protein 29 (Erp29), G-protein coupled
receptor 56 (Gpr56), Tubulointerstitial nephritis antigen-like
(Tinagl1), and Legumain (Lgmn) were disrupted, resulting in the
11xKO cell line. Finally, in the fourth round, we disrupted the
genes encoding YEATS domain-containing protein 2 (Yeats2),
SPARC (Sparc), and Lipoprotein lipase (Lpl), resulting in the
14xKO cell line.
The targets were predominantly identified through proteomics
on spent media or purified product, and we verified that these
genes were, on average among the more abundant transcripts for
secreted proteins, and accounted for proteins exerting a greater
cost to the cell (Fig. 1b). Furthermore, upon quantifying the
amount of ATP liberated upon their deletion, we found their
deletion led to a significantly higher amount of resources
eliminated (p « 1 × 10−5, randomization test), when compared
to a comparable number of randomly selected genes.
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We verified gene disruption at the genomic and proteomic
levels. Specifically, we used MiSeq analysis (Table 1) to verify that
all indels led to frameshift mutations except for the one generated
in LGALS3BP, which leads to a partly scrambled amino acid
sequence and the introduction of a stop codon after residue 44.
Mass spectrometry was subsequently used to verify the absence of
our target proteins after gene disruption. Supernatants from wild-
type CHO-S (WT) and the 6xKO, 11xKO, and 14xKO cell lines
were analyzed for the presence of peptides derived from the target
proteins (Fig. 2a–c). Except for the target YEATS2, peptides were
detected for all of the targets in WT. No or very few peptides were
detected in the 6xKO, 11xKO, and 14xKO cell lines as compared
to WT for all targets except LGALS3BP. Approximately 10–20%
of LGAL3SBP peptides derived from the region upstream of the
editing site were still present in all knockout cell lines, indicating
secretory downregulation of the partial non-sense protein
produced by the frameshift mutation. All other targets were no
longer detected.
KOs display improved growth and less HCP content. To assess
the properties of our knockout cell lines, we followed their growth
and viability for 7 days in shake flasks with daily sampling to
measure viable cell density (VCD), cell viability, and HCP content
(Fig. 3). Interestingly, cell density and viability of knockout cell
lines were improved over WT (Fig. 3a). While the 6xKO cell line
displayed an intermediate phenotype, growth of the 11xKO and
14xKO cell lines was enhanced to reach a VCD of ~7.6 million
cells per milliliter. WT reached a VCD of ~5.4 million cells per
milliliter. Viability of WT started to decrease on the fifth day of
culture, while the knockout cell lines remained above 90% via-
bility for the duration of the experiment. Samples were analyzed
using a CHO HCP detection kit and showed a remarkable
reduction in HCP content as compared to WT (Fig. 3b). Whereas
the 6xKO cell line shows an intermediate phenotype again, the
11xKO and 14xKO cell lines behave similarly, showing an HCP
reduction to ~150 μg mL−1. As the VCD of the knockout cell
lines is higher, the behavior of the cell lines can arguably better be
described by calculating specific HCP productivities. Specific
HCP productivity was found to be 13.5 picograms per cell per day
(pcd) for WT, whereas the 6xKO, 11xKO, and 14xKO cell lines
were reduced to 9.9, 5.7 and 5.6 pcd, respectively (Fig. 3c). Spe-
cific HCP productivity was found to be reduced by 27%, 58% and
59% for the 6xKO, 11xKO, and 14xKO cell lines, respectively, as
compared to WT (Fig. 3d). Besides the improvements in growth
characteristics during batch cultivation, we encountered an
unexpectedly high reduction in HCP content. As it could be
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Fig. 1 Substantial resources can be liberated by targeting HCPs in the CHO secretome. a Proteins produced through the secretory pathway account for
more than 40% of the cell’s biosynthetic capacity, and roughly 1/4 of this cost is dedicated to secreted proteins. b Following proteomic analysis of the
HCCF, 14 proteins (associated with 13 gene loci) were identified and targeted for deletion. The bioenergetic cost of protein synthesis and secretion of these
target genes was quantified as ATP cost per reads mapping to gene per million reads in the transcriptome (RPM). Deletion will free up significantly more
bioenergetic resources than expected from the deletion of a similar number of randomly selected genes (p « 1 × 10−5). This randomization test was a one-
sided test and, as it is not a multiple comparison, no adjustment was made. Source data are provided as a Source Data file.
Table 1 Selection of targets and MiSeq verification of knockouts.
Cell line Target Protein name Uniprot Rationale Location Frameshift
6xKO BGN Biglycan G3HSX8 A Secreted +1
TIMP1 Metalloproteinase inhibitor 1 G3IBH0 A/C Secreted −5/−2/+1
LGALS3BP Galectin-3-binding protein G3H3E4 A/C Membrane +33
NID1.1 Nidogen-1 G3HWE4 A/C Membrane/matrix +1
NID1.2 Nidogen-1 G3I3U5 A/C Membrane/matrix +1
CTSD Cathepsin D G3I4W7 A/C/Q Lysosome −8
11xKO Aga N(4)-(Beta-N-acetylglucosaminyl)-L-
asparaginase
G3HGM6 A Secreted −40
Erp29 Endoplasmic reticulum resident protein 29 G3H284 A ER −1
Gpr56 G-protein coupled receptor 56 G3I3K5 A/C Membrane +1
Tinagl1 Tubulointerstitial nephritis antigen-like G3H1W4 A/C Secreted +1
Lgmn Legumain G3I1H5 A/C/Q Lysosome +1
14xKO Yeats2 YEATS domain-containing protein 2 G3I3I8 A Nucleus +1
Sparc SPARC G3H584 A/C Secreted −5
Lpl Lipoprotein lipase G3H6V7 A/C/Q Membrane/secreted +1
The target names, full protein names, UniProt identifiers, rationale for deletion, subcellular location, and indel size are indicated. Source data are provided as a Source Data file.
A abundance, C copurifying, Q quality.
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argued that the HCP-reduced phenotype is an artifact of the
knockout procedure, we determined the HCP content of unre-
lated cell lines harbouring multiple knockouts generated using the
same procedure. No significant decrease in HCP content of WT
CHO-S and the knockout cell lines is observed (Supplementary
Fig. 1), showing that the HCP-reduced phenotype is specifically
caused by the removal of our targeted proteins. To gain a better
understanding of the impact of these knockouts, we measured
several basic cell properties and established whether mAb pro-
ductivity was affected.
KOs display higher productivity and less HCCF total protein.
To assess several basic cell properties and protein productivity, we
generated stable pools expressing the monoclonal antibody
Rituximab (Rit). We cultivated the WT, WT Rit, 6xKO Rit,
11xKO Rit, and 14xKO Rit cell lines for 4 days in shake flasks and
collected HCCF and cell pellets. We analyzed HCP content,
protein content of HCCF and cells, cell size, transfection effi-
ciency, antibody staining efficiency, and Rituximab titer (Fig. 4
and Supplementary Fig. 2). The HCP-reduced phenotype was
observed as before (Supplementary Fig. 2b), while VCD was
similar for all cell lines (Supplementary Fig. 2a). The total protein
content of the HCCF obtained from the knockout cell lines was
significantly reduced by ~50% (Fig. 4a), while cell size was
reduced from 13.4 μm to 12.5 μm (Supplementary Fig. 2c). The
protein content per cell remained unchanged at ~150-pg protein
per cell (Fig. 4b), which corresponds well with published values
using a CHO-K1 cell line32. Antibody productivity in cell pools
was assayed in two ways: (1) by an antibody staining method
and subsequent FACS analysis (Fig. 4c) and (2) by biolayer
interferometry (Fig. 4d). The knockout cell lines displayed higher
productivity as compared to WT using both methods. Whereas
productivity increased with the number of knockouts using the
staining method, it is only increased until the 11xKO cell line
using biolayer interferometry. Transfection efficiency was similar
for all cell lines (Supplementary Fig. 2d). Based on these results,
we selected high-producing clones to analyze their growth
properties under fed-batch conditions. During selection, the
14xKO Rit cell line displayed a low single-cell survival rate and no
clones could be selected that displayed sufficiently high mAb
productivity. Based on these observations and as the HCP-
reduced phenotype was not decreased further in the 14xKO cell
line, we excluded the 14xKO Rit cell line from further study.
KOs display decreased HCP content in fed-batch cultivation.
After selecting high mAb-producing clones of the WT Rit, 6xKO
Rit, and 11xKO Rit cell lines, we analyzed their growth properties,
productivity, and HCP content in Ambr (Supplementary Fig. 3)
and DASGIP bioreactors (Fig. 5). The goal of these experiments
was to compare behavior of clones in different media and to
generate material for downstream processing. In addition, we
wanted to ensure that high producers could be generated using
the knockout cell lines and that these retained the HCP-reduced
phenotype under controlled cultivation conditions.
Media screening using the Ambr bioreactor revealed that high-
producing mAb clones could be selected from all remaining
knockout mutants (Supplementary Fig. 3). As productivity was
most comparable across mutants in FortiCHO medium, we
selected this medium to scale up cultivation in a DASGIP
bioreactor (Fig. 5). To limit the contribution of lysed cells to HCP
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Fig. 2 Verification of knockouts by mass spectrometry. Supernatant samples prepared from WT (red bars) were subjected to MS and compared to the
a 6xKO (green bars), b 11xKO (blue bars) and c 14xKO (gray bars) cell lines with respect to the indicated targets. Ion counts were normalized to the levels
detected in WT. The target YEATS2 was not detected (ND) in both WT and the 14xKO cell line. All data are presented as mean values ± SD (n= 3
independent experiments). Source data are provided as a Source Data file.
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content in the downstream process, we harvested when the first
culture dropped below 90% viability (Fig. 5a, arrow). Maximum
VCD of WT Rit and the 11xKO Rit cell lines were comparable
(Fig. 5a), while the VCD of the 6xKO Rit cell line was ~50% lower
(also observed in the Ambr bioreactor). However, Rituximab titer
at harvest (Fig. 5b) of the 6xKO Rit cell line was comparable to
WT Rit, while the 11xKO Rit cell line produced ~ 40% less. HCP
titer reduction of the 6xKO Rit and 11xKO Rit cell lines was even
more pronounced under these circumstances. Whereas the WT
Rit cell line produces 1080 μg mL−1 HCP, the 6xKO and 11xKO
cell lines behave similarly and produce ~200 μg mL−1 HCP
(Fig. 5c). Specific HCP productivity was 19.7 pcd for WT Rit,
whereas the 6xKO Rit and 11xKO Rit cell lines were reduced to
5.9 and 4.8 pcd, respectively (Fig. 5d). To emphasize the
substantial improvement in product purity, we calculated the
mAb/HCP ratio, which is improved 7-fold in the 6xKO Rit cell
line and 2-fold in the 11xKO cell line (Fig. 5e). Additional clones
also displayed improved mAb/HCP ratios (Supplementary Fig. 4),
showing that the observed phenotype is not caused by clonal
variation. Importantly, these experiments show that, under
controlled cultivation, our knockout cell lines retain the strongly
HCP-reduced phenotype and improved product purity. In
addition, as the selection process of mAb producers required
more than 56 days in culture, the observed phenotype was stable
for at least 64 generations.
mAb purification results in a pure and bioactive product. To
assess the effect of the knockouts on downstream purification, we
performed protein A affinity chromatography, followed by cation
exchange chromatography (CIEX) and anion exchange chroma-
tography (AIEX) (Supplementary Fig. 5). Samples were collected
after every chromatographic step and were analyzed with respect
to mAb concentration and HCP content. Using these data, we
calculated mAb purification efficiency, HCP content per mg mAb
in ppm, and HCP log reduction values (LRV) (Table 2). Pur-
ification efficiency ranges from 35% to 55% and total HCP LRV
of the process ranges from 4.4 to 5.8. HCP content after three
chromatographic steps was 45 ppm, 18 ppm, and 3 ppm for the
WT Rit, 6xKO cell, and 11xKO cell lines, respectively. Besides the
decrease in HCP content in the 11xKO cell line throughout mAb
purification, we also observed an increase in HCP clearance
during protein A chromatography of one order of magnitude.
To ensure that the mAb product quality was not affected by the
HCP knockouts, the Rituximab product from the mutant clones
was subsequently subjected to glycosylation analysis33,34 (Supple-
mentary Fig. 6a) and in vitro binding to a cell line expressing
CD20, the cellular target of Rituximab (Supplementary Figs. 6b
and 7). The glycosylation profile and bioactivity of Rituximab
produced in the knockout cell lines were found to be very similar
to wild-type produced Rituximab. The stability of mAb
glycosylation was also supported by RNA-Seq analysis of the
WT, 6XKO, and 11XKO cell lines, wherein glycosylation was not
significantly perturbed (Supplementary Tables 1 and 2 and
Supplementary Figs. 8–10). We conclude that the HCP-reduced
phenotype is maintained throughout a representative down-
stream process and that the bioactivity of the product is not
perturbed.
Discussion
The yield of recombinant proteins during biomanufacturing has
steadily increased over the past decades. Thus, downstream
processing has become a bottleneck in biotherapeutic produc-
tion35. Efforts to alleviate this have mostly focused on innovations
in process design to improve downstream processing capacity,
speed, and economics36,37. It has also been suggested that cell line
engineering could be used to reduce or remove problematic
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HCPs, lessening the need for additional purification steps6,38.
Indeed, researchers have specifically removed unwanted proteins
from CHO cell lines that affect product quality1,2,11,12. In addi-
tion, it has recently been shown that depletion of a highly
abundant mRNA encoding a non-essential protein can improve
growth and product titer, indicating that it is possible to free up
energetic and secretory resources by rational cell line engineering
strategies39. This observation was supported by a model of the
secretory pathway, which was able to accurately predict the
increase in growth and protein productivity24. These studies have
so far been limited to single engineering targets, but could easily
be applied on a larger scale. Although different in approach, a
recent paper pioneers the use of inducible downregulation of
non-product related protein expression leading to an increase in
the purity of the biopharmaceutical product40. Knowledge-based
decisions can support purity-by-design approaches and could
lead to easier downstream purification processing.
Here, we hypothesized that removal of HCPs by targeted gene
disruption will lead to improvements in cell growth, secretory
pathway capacity, and DSP. We used computational modeling to
demonstrate that CHO cells spend substantial resources on the
host cell secretome. We proceeded with the removal of 14 HCPs,
which were more highly abundant in CHO HCCF. We also
prioritized targets that can be difficult-to-remove or that influ-
ence product quality. Surprisingly we found the removal of these
14 HCPs led to a substantial decrease in HCP content of up to
70% and HCCF total protein content of up to 50%. The observed
phenotype persists under controlled cultivation and is specifically
caused by the knockouts. The HCP-reduced phenotype was stable
over many generations and was observed in multiple clones. The
ability to generate high mAb producers was not perturbed in the
6xKO and 11xKO cell lines and the resulting mAb product was
shown to be indistinguishable from a mAb produced in a wild-
type CHO cell line.
Improvements in product purity will considerably facilitate the
purification of mAbs to acceptable HCP levels, especially in those
situations where HCPs form a challenge in the purification or
quality of a biotherapeutic protein. It is tempting to speculate that
one of the ion exchange chromatography steps could be omitted
from the downstream purification process. However, besides the
removal of HCP impurities, ion exchange chromatography is also
used to reduce high molecular weight aggregates, charge-variants,
residual DNA, leached Protein A, and viral particles41. It remains
to be seen whether two chromatographic steps can bring other
product- and process-related impurities within regulatory
requirements. The results presented here certainly warrant a
detailed analysis of the HCP-reduced cell lines under industrial
mAb production conditions with respect to growth, production,
and mAb critical quality attributes.
Systems biology approaches and omics data analysis provide
useful tools for screening and prioritizing HCPs that are more
likely to free up greater amounts of cellular resources upon
removal24,42. Through a multiplex genome editing approach, we
successfully removed more than half of the HCPs in CHO cells by
mass. This demonstration highlights that large-scale genome
editing in mammalian cells can be done for bioproduction, and
can have benefits throughout the bioproduction process. In
particular, such efforts can be effectively used to make clean CHO
cells by eliminating many undesirable HCPs6 and retroviral-like
particles22,43 that currently require extensive purification
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Fig. 4 Knockout cell lines display increased productivity and less HCCF protein content. a HCCF protein content, b protein content per cell, c staining
efficiency, and d Rituximab titer of WT (black), WT Rit (red), 6xKO Rit (green), 11xKO Rit (blue), and 14xKO Rit (gray) cell lines. All properties were
measured after cultivation for 4 days in shake flasks. Data are presented as mean values ± SD (n= 3 independent experiments) except for the staining
efficiency determination. Statistical analysis (a, b, d) was performed using one-way ANOVA followed by Tukey’s post-hoc test (ns= not significant).
Source data are provided as a Source Data file.
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strategies. Through this, one may obtain higher quality drugs and
produce these at lower costs.
Methods
Cell culture and cell line generation. All cell lines described here were created
using CHO–S cells (Life Technologies, Carlsbad, CA, USA). Knockout cell lines
were generated by transfecting with expression vectors encoding GFP_2A_Cas9
and sgRNAs14. Fluorescent cells were single-cell sorted by FACS on day 2 after
transfection. Primers used in this study are listed in Supplementary Data 2.
Viability, cell size and VCD was monitored using the NucleoCounter NC‐200 Cell
Counter (ChemoMetec, Allerod, Denmark). Batch cultivation was performed in
250 mL shake flasks containing 60–80 mL CD-CHO medium (Thermo Fisher
Scientific, Waltham, MA, USA) supplemented with 8 mM L-glutamine (Life
Technologies) and 0.2% anti-clumping reagent (Life Technologies). Cells were
extracted from the cell bank and thawed in 10-mL pre-warmed medium. Cultures
were passaged three times during 7 days and strained through a 40-µm filter before
inoculation. Cultivation was performed in a humidified shaking incubator operated
at 37 °C, 5% CO2 and 120 rpm.
Prior to inoculation into fed-batch bioreactors, cells were adapted from CD-
CHO medium to FortiCHO (Gibco, Carlsbad, CA, USA), OptiCHO (Gibco), or
ActiPro (GE Healthcare, Chicago, IL, USA) medium during three passages. All
media were supplemented with 1% Anti-Anti (Life Technologies), 0.1% anti-
clumping agent (Life Technologies), and 8 mM L-glutamine (Lonza, Basel,
Switzerland). Fed-batch cultivation was performed in a DASGIP Mini bioreactor
(Eppendorf, Jülich, Germany) containing between 260 and 280 mL medium or in
an Ambr 15 bioreactor system (Sartorius, Göttingen, Germany) containing 14.4 mL
medium. Temperature was maintained at 37 °C. In the DASGIP, dissolved oxygen
(DO) was maintained at 40% by cascade aeration strategy (Air/Air&O2/O2) using
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Fig. 5 The HCP-reduced phenotype is maintained under fed-batch cultivation. a Viability and VCD, b Rituximab titer, c HCP profile, d specific HCP
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Table 2 Knockout cell lines display reduced HCP content
during a purification process.
HCCF Protein A CIEX AIEX Total
WT mAb (µg) 38,470 33,135 26,371 17,088
Purification
yield (%)
86.1 79.6 64.8 44.4
HCP (ppm) 1,795,217 7243 158 45
LRV 2.4 1.7 0.5 4.6
6xKO mAb (µg) 43,480 41,891 31,904 24,104
Purification
yield (%)
96.3 76.2 75.6 55.4
HCP (ppm) 472,873 1596 74 18
LRV 2.5 1.3 0.6 4.4
11xKO mAb (µg) 12,180 10,881 7377 4308
Purification
yield (%)
89.3 67.8 58.4 35.4
HCP (ppm) 1,638,998 551 47 3
LRV 3.5 1.1 1.2 5.8
The HCCF, protein A elution pool, CIEX elution pool, and AIEX flow through pool of WT Rit,
6xKO Rit, and 11xKO Rit were subjected to mAb and HCP titer measurements. These values
were used to calculate yield, HCP LRV, and HCP content in ppm. Mean of technical duplicates
is shown.
CIEX cation exchange, AIEX anion exchange, LRV log reduction value, ppm parts per million.
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nitrogen as a carrier gas (total flow rate 1–3 L h−1). In the Ambr, DO was
maintained at 40% using pure O2 using nitrogen as carrier gas (total flow rate
0.200 sL h−1). Agitation rate (200–400 rpm) was adjusted on a daily basis to keep
DO set point at 40%. Culture pH was maintained at 7.1 ± 0.02 (DASGIP) or 7.1 ±
0.05 (Ambr) using intermittent addition of CO2 to the gas mix and 1M CHNaO3.
HyClone Cell Boost 7a supplement (GE Healthcare) containing 500 mM glucose
and HyClone Cell Boost 7b Supplement (GE Healthcare) were fed daily when cell
numbers reached 1.4–2.2 × 106 cells mL−1 at 2% and 0.2% of daily total volume,
respectively. Glucose (2220 mM) and glutamine (200 mM) were used to maintain
levels between 24 and 30 mM, and 3–5 mM, respectively, via a once-daily feeding
based on measured concentration, doubling time, and consumption rates. Anti-
foam C (Sigma, St. Louis, MI, USA) was supplemented when needed.
Deep sequencing analysis of genome edit sites. Confluent colonies from 96-well
flat-bottom replicate plates were harvested for genomic DNA extraction. DNA
extraction was performed using QuickExtract DNA extraction solution (Epicentre,
Madison, WI, USA) according to the manufacturer’s instruction. The library
preparation was based on Illumina 16S Metagenomic Sequencing Library. Pre-
paration and deep sequencing were carried out on a MiSeq Benchtop Sequencer
(Illumina, San Diego, CA). The protocol for amplifying the CRISPR-targeted
genomic sequences, amplicon purification, adapter-PCR, and quality analysis fol-
lowed our previously published methods14.
Generation of antibody expressing cell lines. WT and knockout cell lines
(6xKO, 11xKO, and 14xKO) were initiated from cryopreserved vials and passaged
for 1 week prior to transfection. Transfection efficiency was determined by
transfecting the pMAX-GFP (Lonza) and subsequent FACS analysis. Cells were
transfected with a plasmid encoding the antibody Rituximab and the zeocin
selection gene using Freestyle MAX reagent and maintained for 2 days before
selection pressure was initiated with zeocin (400 µg mL−1). After 21 days of
selection, viability was above 95% in all cultures and pools were stored in vials
containing 10% DMSO. To enrich for clones with high productivity, immunos-
taining of Rituximab on the plasma membrane (surface staining) was performed on
the Rituximab expressing cell pool by staining for 30 min at 4 °C with 5 µg mL−1
anti‐human IgG antibody conjugated to FITC (Invitrogen, Carlsbad, CA, USA) and
subsequent single-cell sorting using fluorescence activated cell sorting (FACS) and
expansion. To select clones with the highest productivity, we used the titer-to-
confluency method44. Confluency was determined on a Celigo cytometer (Nex-
celom Bioscience, Lawrence, MA, USA) and titer was determined using biolayer
interferometry. The number of clones screened by this method was 1000 (WT), 480
(6xKO), 1760 (11xKO), and 480 (14xKO).
Quantification of secretome costs. A genome-scale model of protein secretion
was adapted for use here24 using MATLAB 2018B [https://github.com/
LewisLabUCSD/CHOSecretoryKO]. Briefly, this model was adapted to focus on
the bioenergetic costs of protein synthesis and translocation of each host-cell
secreted protein. Information on each secreted protein in CHO cells was obtained,
including mRNA and protein sequence, signal peptides, etc. We then simulated the
cost of producing each protein. Each cost was scaled by the measured mRNA levels
using published RNA-Seq from CHO–S cells grown under similar conditions25,
and this was used as a proxy for the relative resources allocated to each secreted
protein. Entrez gene identifiers were matched to their corresponding entry number
in the UniProt database to determine presence of signal peptide. For those genes
without a UniProt match, we used the online tool PrediSi45 to determine the
presence of a signal peptide. To estimate ATP cost of secretion for all secreted
genes identified, we added the following costs, adapted from the genome-scale
model of protein secretion24. First, the energy cost of protein translation was equal
to 4xL ATP molecules where L is the length of the amino acid sequence. Next, the
average cost of signal peptide degradation was equal to 22 ATP molecules. Finally,
the energetic cost of translocation across ER membrane was equal to L/40+ 2.
From this, we were able to quantify what proportion of all secreted protein was
eliminated in our study.
Identification of HCPs by mass spectrometry. WT CHO–S was cultivated in
duplicate in three separate DASGIP Mini bioreactor experiments. HCCF was
obtained during late exponential phase by centrifugation at 500×g for 10 min.
Samples were TCA-precipitated with an overnight incubation in ice cold acetone,
and the dry protein pellet was dissolved in 100 μl 8 M urea. Samples were treated
first with 100 mM DTT (5 μl) and incubated at 37 °C for 45 min and then with
100 mM iodoacetamide (10 µl) and incubated in the dark for 45 min. Samples
containing 100 µg of protein were digested overnight at 37 °C using trypsin after
which 10% TFA was added, and samples were stage tipped. Data were acquired on
Synapt G2 (Waters) Q-TOF instrument operated in positive mode using ESI with a
NanoLock-spray source. During MSE acquisition, the mass spectrometer alternated
between low and high-energy mode using a scan time of 0.8 s for each mode over a
50–2000-Da interval. Nanoscale LC separation of the tryptic digested samples was
performed using a nanoAcquity system (Waters, Milford, MA, USA) equipped a
nanoAcquity BEH130 C18 1.7 μm, 75 μm× 250 mm analytical reversed-phase
column (Waters). A reversed-phase gradient was employed to separate peptides
using 5–40% acetonitrile in water over 90 min with a flow rate of 250 nL min−1 and
a column temperature of 35 °C. The data were analyzed using the Progenesis QI
software v2.4 (NonLinear dynamics), which aligns the different runs ensuring that
the precursor ions and identifications can be shared in between runs.
HCP, antibody, and protein quantification. HCP and antibody titers were
quantified using biolayer interferometry on an Octet RED96 (Pall, Menlo Park, CA,
USA). For HCP quantification, the anti-CHO HCP Detection Kit (Pall) was used
according to the manufacturer’s specifications. When needed, samples were diluted
in sample diluent buffer before analysis. For Rituximab quantification, protein A
biosensors (Pall) were equilibrated in PBS, and Rituximab was measured for 120 s
at 30 °C. Absolute concentrations of Rituximab were calculated by comparison with
a calibration curve generated from a dilution series of a human IgG control (31154,
Thermo Fisher Scientific or A01006, Genscript, New Jersey, NJ, USA). When
needed, samples were diluted in conditioned medium to fall within the range of the
calibration curve. Regeneration of biosensor tips between measurements was per-
formed in 10 mM glycine pH 1.7. The protein concentration of HCCF, cell extracts,
and purified Rituximab was measured using a Nanodrop 2000 (Thermo Fisher
Scientific). Before analysis, HCCF was TCA-precipitated, and whole cells were
lysed using RIPA buffer. Rituximab was quantified using an extinction coefficient
of 1.6 (A280 nm, 0.1% solution).
Protein purification and glycan analysis. Cell-free supernatants were prepared by
centrifugation and directly loaded (100 mL) onto a 5-mL HiTrap MabSelect col-
umn (GE Healthcare). After washing the column with binding buffer (20 mM
sodium phosphate, 0.15M NaCl, pH 7.2), Rituximab was eluted with elution buffer
(0.1 M sodium citrate, pH 3.5) into collection tubes containing 1 M TRIS-HCl, pH
9.0. The fractions containing Rituximab were pooled, diluted 10 times with 50 mM
MES pH 6.0, and loaded onto a 5 mL HiTrap SP FF column (GE Healthcare). After
washing the column with binding buffer (50 mM MES pH 6.0, 40 mM NaCl),
Rituximab was eluted with elution buffer (50 mMMES pH 6.0, 200 mM NaCl). The
fractions containing Rituximab were pooled, diluted 5 times with 20 mM TRIS pH
8.0, and loaded onto a 5-mL HiTrap Q FF column (GE Healthcare) equilibrated in
buffer A (20 mM TRIS-HCl, 40 mM NaCl). The flow through containing Ritux-
imab was collected and concentrated to 5 mgmL-1. Samples for HCP and mAb
titer analysis were collected after every chromatographic step. The final mAb
samples were aliquoted, snap frozen in N2 (l) and stored at −80 °C. N-linked
glycans were released from purified Rituximab (12 µg) and fluorescently labeled
with the GlycoWorks RapiFluor-MS N-Glycan Kit (Waters, Milford, MA, USA).
Data were subsequently collected on a Thermo Ultimate 3000 UHPLC system
equipped with a RS Fluorescence detector and coupled to a Thermo Fisher Velos
pro iontrap MS run in positive mode. The separation gradient was 30–43% 50mM
ammonium formate buffer. The amount of N-glycan was determined by inte-
grating the areas under the normalized fluorescence spectrum peaks with Thermo
Xcalibur software v4.3 (Thermo Fisher Scientific) giving normalized, relative glycan
quantities.
Rituximab cell binding assay. Rituximab was purified via a MabSelect column
(GE Healthcare) and diluted to 5 µg mL−1 using dilution buffer (PBS containing
3% BSA). These solutions were diluted further to respectively 2, 1, 0.5, 0.1, and
0.01 µg mL−1 using dilution buffer. Ramos cells (2 × 105 cells per well; DSMZ, ACC
603) were blocked with PBS containing 5% BSA for 10 min and incubated with
100 µL of the Rituximab dilutions for 1 h at 4 °C. Cells were washed three times
with PBS and subsequently incubated for 30 min at 4 °C with 5 µg mL−1
phycoerythrin-conjugated goat F(ab′)2 anti-human IgG (Abcam, Cambridge, UK)
as secondary antibody. After washing the cells 3x with PBS, binding was quantified
in triplicate by flow cytometry using MACSQuant analyzer 10 VYB (Miltenyi
Biotec, Bergisch Gladbach, Germany). Jurkat cells were used as CD20 negative cell
line and a Rituximab biosimilar antibody (R&D systems, Minneapolis, MN, USA)
was included as reference anti-CD20 antibody at the indicated dilutions. Analysis
was performed using FlowJo v10 (BD Biosciences). A representative gating strategy
is presented in Supplementary Fig. 7. Raw data and statistics are presented in
Supplementary Data 3.
RNA sample preparation and sequencing. WT Rit, 6xKO Rit, 11xKO Rit cells
(5 × 106) sampled from the DASGIP bioreactor on days 4, 6, and 8 were resus-
pended in RLT buffer (Qiagen, Hilden, Germany) containing 40-mM DTT. After
storage at −80 °C, RNA was extracted using the RNeasy kit (Qiagen) followed by
on-column DNAse digestion. RNA was eluted in 40 µl nuclease-free water, con-
centration was measured by Qubit (Thermo Fisher scientific) and the purity was
checked on a Fragment Analyzer (Advanced Analytical). Complementary DNA
synthesis was obtained from 1 μg of RNA using the High capacity cDNA RT kit
(Thermo Fisher scientific). Samples were diluted to 60 ng µL−1 in 50 µL and library
preparation was performed with the TruSeq Stranded mRNA Library Prep Kit
(Illumina, San Diego, CA, USA). Final RNA libraries were first quantified by Qubit
and the size was checked on a Fragment Analyzer. Libraries were normalized to
10 nM and pooled and the final pool of libraries was run on the NextSeq platform
with high output flow cell configuration (NextSeq® 500/550 High Output Kit v2,
300 cycles, Illumina). Raw data is deposited at the Gene Expression Omnibus and
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Short Read Archive with accession number GSE144624 [https://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE144624].
RNA-Seq quantification and differential gene expression. RNA-Seq quality was
assessed using FastQC. Adapter sequences and low quality bases were trimmed
using Trimmomatic46. Sequence alignment was performed using STAR47 against
the CHO genome (GCF_000419365.1_C_griseus_v1.0) with the default para-
meters. The expression of each gene was quantified using HTSeq48. We performed
differential gene expression analysis using DESeq249. After Benjamini-Hochberg
FDR correction, genes with adjusted p-values < 0.05 and fold change >1.5 were
considered as differentially expressed genes (DEGs).
GSEA and enrichment strength analysis. Gene set enrichment analysis (GSEA)
was performed using the Broad Institute GSEA software50. A ranked list of genes
(adjusted p-values < 0.05) using the differential expression values (fold change in
the log2 scale) was run through the GSEA pre-ranked protocol. GSEA-pre-rank
analysis was processed to detect significant molecular signature terms using
MSigDB’s Hallmark, Reactome, KEGG, and Gene Ontology Biological Process
gene sets for the differential expressed genes. A molecular signature term was
deemed significant if (1) after Benjamini–Hochberg false discovery correction,
the molecular signature term has an adjusted p-value < 0.05; and (2) there are
≥10 genes presented in our gene list for the molecular signature term. The
leading-edge analysis allows for the GSEA to determine which subsets (referred
to as the leading-edge subset) of genes primarily contributed to the enrichment
signal of a given gene set’s leading-edge or core enrichment50. The leading-edge
analysis is determined from the enrichment score (ES), which is defined as the
maximum deviation from zero. The enrichment strength describes the strength
of the leading-edge subset of a gene set (i.e., the interferon-alpha response in this
study)50. Specifically, if the gene set is entirely within the first N positions in the
ranked differentially expressed gene list, then the signal strength is maximal or
100%. If the gene set is spread throughout the list, then the signal strength
decreases towards 0%.
Statistics and reproducibility. Statistical parameters including the exact value of
n, p values, and the types of the statistical tests are reported in the figures and
corresponding figure legends. Statistical analysis was carried out using Prism 8.4
(GraphPad Software). Statistical analysis was conducted on data from three or
more biologically independent experimental replicates. Data distribution was
assumed to be normal, but this was not formally tested. Comparisons between
groups were planned before statistical testing and target effect sizes were not
predetermined. Error bars displayed on graphs represent the mean ± SD of at least
three independent experiments. Most experiments report technical replicates,
whereas biological variability was addressed in the clonal variation experiment.
*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 were considered significant.
The experiment that confirms the HCP-reduced phenotype in bioreactors was
independently performed three times with similar results. No data was excluded
from the study.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Raw RNA-Seq data that support the findings of this study have been deposited at the
Gene Expression Omnibus and Short Read Archive with the accession number
GSE144624 [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE144624]. The
authors declare that all other data supporting the findings of this study are available
within the paper and its supplementary information files. The source data for Figs. 1–5,
Table 1, and Supplementary Figs. 1–4 and 6 are provided as a source data file.
Code availability
The code used for the analysis performed in this study is available at [https://github.com/
LewisLabUCSD/CHOSecretoryKO].
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